Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API

Neurological Disorders and Treatments

716 ta ish

  1. FEATURES OF EARLY DIAGNOSIS OF DIABETIC NEPHROPATHY

    Shoira Kodirova

    MaqolaChronic Kidney Disease and DiabetesOpen MIND20260 iqtibos
    ABI

  2. ADAPTIVE CHANGES OF TISSUES: MORPHOLOGICAL AND FUNCTIONAL ANALYSIS

    Shoxrullo Saidov, Aziza Bekmurodova

    MaqolaRegulation of Appetite and ObesityOpen MIND20260 iqtibos
    ABI

  3. FEATURES OF EARLY DIAGNOSIS OF DIABETIC NEPHROPATHY

    Shoira Kodirova

    MaqolaChronic Kidney Disease and DiabetesZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  4. ADAPTIVE CHANGES OF TISSUES: MORPHOLOGICAL AND FUNCTIONAL ANALYSIS

    Shoxrullo Saidov, Aziza Bekmurodova

    MaqolaRegulation of Appetite and ObesityZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  5. ISCHEMIC STROKE: PATHOPHYSIOLOGY, DIAGNOSIS, AND MODERN THERAPEUTIC APPROACHES

    Abduraupova Maftuna Yunusjon qizi

    MaqolaAcute Ischemic Stroke ManagementOpen MIND20260 iqtibos
    ABI

  6. ISCHEMIC STROKE: PATHOPHYSIOLOGY, DIAGNOSIS, AND MODERN THERAPEUTIC APPROACHES

    Abduraupova Maftuna Yunusjon qizi

    MaqolaAcute Ischemic Stroke ManagementZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  7. SURUNKALI YURAK YETISHMOVCHILIGI, XALQARO TAVSIYALAR BO'YICHA 2 DIAGNOSTIKASI, DAVOLASH VA PROFILAKTIKASI

    Nozima Khosilbek kizi Yusupova, Saytullo Yusupov

    MaqolaNeuropeptides and Animal PhysiologyOpen MIND20260 iqtibos
    ABI

  8. SURUNKALI YURAK YETISHMOVCHILIGI, XALQARO TAVSIYALAR BO'YICHA 2 DIAGNOSTIKASI, DAVOLASH VA PROFILAKTIKASI

    Nozima Khosilbek kizi Yusupova, Saytullo Yusupov

    MaqolaNeuropeptides and Animal PhysiologyZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  9. КЛИНИЧЕСКИЕ И БИОХИМИЧЕСКИЕ ПОКАЗАТЕЛИ ПОСЛЕ ИНСУЛЬТА В ПЕРИОД АМБУЛАТОРНОГО НАБЛЮДЕНИЯ

    Нилуфар Каххаровна Саломова

    MaqolaNeurological Disorders and TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  10. КЛИНИЧЕСКИЕ И БИОХИМИЧЕСКИЕ ПОКАЗАТЕЛИ ПОСЛЕ ИНСУЛЬТА В ПЕРИОД АМБУЛАТОРНОГО НАБЛЮДЕНИЯ

    Нилуфар Каххаровна Саломова

    MaqolaNeurological Disorders and TreatmentsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  11. QANDLI DIABETNING 2-TURI RIVOJLANISHIDA SEMIZLIKNING ASOSIY XAVF OMILI SIFATIDAGI O'RNI

    Haydarov Asilbek, Kattaboyeva Muhayyo Nurmuhammad qizi

    MaqolaAdipokines, Inflammation, and Metabolic DiseasesOpen MIND20260 iqtibos
    ABI

  12. QANDLI DIABETNING 2-TURI RIVOJLANISHIDA SEMIZLIKNING ASOSIY XAVF OMILI SIFATIDAGI O'RNI

    Haydarov Asilbek, Kattaboyeva Muhayyo Nurmuhammad qizi

    MaqolaAdipokines, Inflammation, and Metabolic DiseasesZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  13. The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance

    Mukhammadali Jumayev

    MaqolaDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  14. The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance

    Mukhammadali Jumayev

    MaqolaDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  15. The place of statins in the treatment of chronic periodontitis in patients with atherosclerosis of the coronary arteries

    Ж.А. Ризаев, I. R. Agababyan

    MaqolaOral microbiology and periodontitis researchExperimental and Clinical Gastroenterology20260 iqtibos
    ABI

  16. The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance

    Mukhammadali Jumayev

    MaqolaDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  17. The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance

    Mukhammadali Jumayev

    MaqolaDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  18. THE DEVELOPMENT OF RETINAL DYSTROPHY IN MYOPIA IN ADOLESCENTS LIVING IN MOUNTAINOUS FOOTHILL AREAS.

    T.J. Usmanova

    MaqolaRetinopathy of Prematurity StudiesOpen MIND20260 iqtibos
    ABI

  19. THE DEVELOPMENT OF RETINAL DYSTROPHY IN MYOPIA IN ADOLESCENTS LIVING IN MOUNTAINOUS FOOTHILL AREAS.

    T.J. Usmanova

    MaqolaRetinopathy of Prematurity StudiesZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  20. STRUCTURAL FEATURES OF SIMPLE AND COMPLEX ENZYMES AND THEIR CHEMICAL COMPOSITION

    Kamola Raximova

    MaqolaEnzyme Catalysis and ImmobilizationOpen MIND20260 iqtibos
    ABI

  21. STRUCTURAL FEATURES OF SIMPLE AND COMPLEX ENZYMES AND THEIR CHEMICAL COMPOSITION

    Kamola Raximova

    MaqolaEnzyme Catalysis and ImmobilizationZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  22. OPTIMIZING THE MANAGEMENT PROCESS OF PATIENTS WITH ARTERIAL HYPERTENSION

    Khayotillo Shakhobiddinov

    MaqolaBlood Pressure and Hypertension StudiesOpen MIND20260 iqtibos
    ABI

  23. NERVOUS TISSUE, NEURON AND NEUROGLIA

    Shoxrullo Saidov, Moxistrabonu Najmiddinova

    MaqolaNerve injury and regenerationOpen MIND20260 iqtibos
    ABI

  24. NERVOUS TISSUE, NEURON AND NEUROGLIA

    Shoxrullo Saidov, Moxistrabonu Najmiddinova

    MaqolaNerve injury and regenerationZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  25. OPTIMIZING THE MANAGEMENT PROCESS OF PATIENTS WITH ARTERIAL HYPERTENSION

    Khayotillo Shakhobiddinov

    MaqolaBlood Pressure and Hypertension StudiesZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI